Prediabetes and the risk of cancer: a meta-analysis

Diabetologia

Volumn 57, Issue 11, 2014, Pages 2261-2269

  Huang, Yi ^a   Cai, Xiaoyan ^a   Qiu, Miaozhen ^b   Chen, Peisong ^c   Tang, Hongfeng ^a   Hu, Yunzhao ^a   Huang, Yuli ^a  

^a SHUNDE HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer; Impaired fasting glucose; Impaired glucose tolerance; Prediabetes; Risk factors

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FOLLOW UP; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIVER CANCER; META ANALYSIS; NEOPLASM; PANCREAS CANCER; PROSPECTIVE STUDY; RISK ASSESSMENT; STOMACH CANCER; COMPLICATION; FEMALE; MALE; NEOPLASMS; PREDIABETIC STATE; RISK FACTOR;

FEMALE; HUMANS; MALE; NEOPLASMS; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84916614291     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3361-2     Document Type: Article

References (42)

1. DeFronzo RA, Abdul-Ghani M (2011) Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 108:3B–24B
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26(Suppl 1):S5–S20
3. World Health Organization (WHO) Consultation (2006) Definition and diagnosis of diabetes and intermediate hyperglycaemia. www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed 1 Jan 2014
4. Ryden L, Grant PJ, Anker SD et al (2013) ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087
5. Forouhi NG, Balkau B, Borch-Johnsen K et al (2006) The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 49:822–827
6. Buysschaert M, Sadikot S (2013) Diabetes and cancer: a 2013 synopsis. Diabetes Metab Syndr 7:247–250
7. Seshasai SR, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841
8. Hirakawa Y, Ninomiya T, Mukai N et al (2012) Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study. Am J Epidemiol 176:856–864
9. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N (2011) Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control 22:1163–1171
10. Parekh N, Lin Y, Vadiveloo M, Hayes RB, Lu-Yao GL (2013) Metabolic dysregulation of the insulin-glucose axis and risk of obesity-related cancers in the Framingham Heart Study-offspring cohort (1971–2008). Cancer Epidemiol Biomarkers Prev 22:1825–1836
11. Stattin P, Bjor O, Ferrari P et al (2007) Prospective study of hyperglycemia and cancer risk. Diabetes Care 30:561–567
12. Yun JE, Jo I, Park J et al (2006) Cigarette smoking, elevated fasting serum glucose, and risk of pancreatic cancer in Korean men. Int J Cancer 119:208–212
13. Zhou XH, Qiao Q, Zethelius B et al (2010) Diabetes, prediabetes and cancer mortality. Diabetologia 53:1867–1876
14. Chung H, Chen S, Li M (2009) Diabetes and risk of death from cancer of the prostate, kidney, and urinary bladder. Urology 74:S36–S37
15. Gwack J, Hwang SS, Ko KP et al (2007) Fasting serum glucose and subsequent liver cancer risk in a Korean prospective cohort. J Prev Med Public Health 40:23–28 [article in Korean]
16. Harding JL, Soderberg S, Shaw JE et al (2012) All-cause cancer mortality over 15 years in multi-ethnic Mauritius: the impact of diabetes and intermediate forms of glucose tolerance. Int J Cancer 131:2385–2393
17. Kowall B, Rathmann W, Heier M et al (2011) Categories of glucose tolerance and continuous glycemic measures and mortality. Eur J Epidemiol 26:637–645
18. Lu W, Resnick HE, Jain AK et al (2003) Effects of isolated post-challenge hyperglycemia on mortality in American Indians: the Strong Heart Study. Ann Epidemiol 13:182–188
19. Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012
20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197
21. Wells GA, Shea B, O’Connell D et al (2003) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 1 Jan 2014
22. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B (2010) Low glomerular filtration rate and risk of stroke: meta-analysis. BMJ 341:c4249
23. Imdad A, Yakoob MY, Bhutta ZA (2011) The effect of folic acid, protein energy and multiple micronutrient supplements in pregnancy on stillbirths. BMC Public Health 11(Suppl 3):S4
24. Stengard JH, Tuomilehto J, Pekkanen J et al (1992) Diabetes mellitus, impaired glucose tolerance and mortality among elderly men: the Finnish cohorts of the Seven Countries Study. Diabetologia 35:760–765
25. Balkau B, Forhan A, Eschwege E (2002) Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia 45:1224–1230
26. Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR (2002) Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 156:349–352
27. Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157:1092–1100
28. Perseghin G, Calori G, Lattuada G et al (2012) Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 15th year of follow-up. Acta Diabetol 49:421–428
29. Shaw J (2011) Diagnosis of prediabetes. Med Clin N Am 95:341–352
30. De Caterina R, Madonna R (2010) Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship. Eur Heart J 31:1159–1162
31. Abe R, Yamagishi S (2008) AGE-RAGE system and carcinogenesis. Curr Pharm Des 14:940–945
32. Rehman A, Nourooz-Zadeh J, Moller W, Tritschler H, Pereira P, Halliwell B (1999) Increased oxidative damage to all DNA bases in patients with type II diabetes mellitus. FEBS Lett 448:120–122
33. Tabak O, Gelisgen R, Erman H et al (2011) Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus. Clin Invest Med 34:E163–E171
34. Pereira CS, Molz P, Palazzo RP et al (2013) DNA damage and cytotoxicity in adult subjects with prediabetes. Mutat Res 753:76–81
35. Faerch K, Borch-Johnsen K, Holst JJ, Vaag A (2009) Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 52:1714–1723
36. Gao S, Li A, Liu F et al (2013) NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell 24:725–737
37. Zhang F, Yang Y, Skrip L et al (2012) Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case–control and 25 cohort studies. Acta Diabetol 49(Suppl 1):S235–S246
38. Frayling TM, Colhoun H, Florez JC (2008) A genetic link between type 2 diabetes and prostate cancer. Diabetologia 51:1757–1760
39. Bullard KM, Saydah SH, Imperatore G et al (2013) Secular changes in U.S. prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999–2010. Diabetes Care 36:2286–2293
40. Nathan DM, Davidson MB, DeFronzo RA et al (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753–759
41. Leone A, Di Gennaro E, Bruzzese F, Avallone A, Budillon A (2014) New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res 159:355–376
42. American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl 1):S67–S74